Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (16)

2022

  1. VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures

    International journal of molecular sciences, Vol. 23, Núm. 15

2021

  1. The neuropeptide vip limits human osteoclastogenesis: Clinical associations with bone metabolism markers in patients with early arthritis

    Biomedicines, Vol. 9, Núm. 12

2020

  1. A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 1

  2. Vasoactive intestinal peptide axis is dysfunctional in patients with Graves’ disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance

    Frontiers in Endocrinology, Vol. 10

  2. Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin

    Cells, Vol. 9, Núm. 1

2018

  1. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Clinical relevance of VPAC1 receptor expression in early arthritis: Association with IL-6 and disease activity

    PLoS ONE, Vol. 11, Núm. 2

  2. Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12: Induction by IL-1β and Fibronectin and Contribution to Cartilage Damage

    American Journal of Pathology, Vol. 186, Núm. 9, pp. 2449-2461

  3. VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts

    Journal of Cellular and Molecular Medicine, Vol. 20, Núm. 4, pp. 678-687

2015

  1. Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity

    Journal of Molecular Neuroscience, Vol. 56, Núm. 3, pp. 577-584

2014

  1. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

    PLoS ONE, Vol. 9, Núm. 1

  2. Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: Modulation by inflammatory mediators and neuropeptides

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 18-27

  3. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 10-17

2013

  1. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts

    Rheumatology (United Kingdom), Vol. 52, Núm. 12, pp. 2177-2186

  2. Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: Immunomodulation by vasoactive intestinal peptide

    NeuroImmunoModulation, Vol. 20, Núm. 5, pp. 274-284